Evaxion Biotech A/S expected to post a loss of 56 cents a share - Earnings Preview

Evaxion A/S

27/05/2024 14:39

* Evaxion Biotech A/S  EVAX.OQ   EVAX.O  is expected to show
a
rise in quarterly revenue when it reports  results on May 29
(estimated) for the period ending March 31 2024
    * The Copenhagen Denmark-based   company is expected to
report
revenue of $37 thousand, according to the mean estimate from 2
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Evaxion Biotech A/S is
for a
loss of 56 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Evaxion
Biotech
A/S is $11.00​, above​ its last closing price of $4.04. ​​​

This summary was machine generated May 27 at 13:39 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)